ment 
Biodesix CEO Scott Hutton and CFO Robin Harper Cowie celebrated the company’s five-year IPO anniversary 
by ringing the Nasdaq closing bell.
Chief Executive Officer Scott Hutton, Chief 
Scientific Officer Gary Pestano, Ph.D., Chief 
Commercial Officer Kieran O’Kane, and 
members of the Biodesix team to fly to New 
York and stand on that famous podium.  
“I couldn’t believe how emotional it was,” 
Cowie says. The Biodesix team has built 
a company dedicated to transforming 
patient care through personalized diag­
nostics, and this was a tangible recognition 
of those efforts.
The 2020 IPO gave Biodesix a major capital 
infusion and marked the starting line for life 
as a public company.
The Louisville-based company operates two 
business lines: personalized diagnostics for 
early detection and treatment guidance of 
lung cancer, the deadliest form of cancer, 
as well as development services to support 
2026-27 BIOSCIENCE COLORADO     29

View this content as a flipbook by clicking here.